PTX Media related, page-1570

Tiger is quite right. Whilst the efficacy resutls are exceptional, the safety profile is not and, in fact, I don't know how the author of the article could possibly refer to the drug as safe given the details:-

"The drug was found to be safe, with manageable side effects, including cytokine-release syndrome in four patients and immune-cell-related neurotoxicity syndrome in three patients. One patient experienced grade 3 sepsis that resolved; the same patient later developed fatal neutropenic septic shock outside the dose-limiting toxicity time frame."

The specific type of NHL being trialed is B-cell non-Hodgkin Lymphoma. From the following list of main subtypes listed on the Lymphoma Aust website, you can see where PTCL and CTCL sit;-






What's interesting is the following slide from our PTX-100 Spotlight Presentation that shows the indications of interest for PTX-100:-